Intelligence / Healthtech / New Clinical Trials / ScandiBio Therapeutics AB
Clinicaltrial registered22 Oct 2026
ScandiBio Therapeutics AB
22 Oct 2026: Trial registered · Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 22 Oct 2026
- Title
- Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout
- Conditions
- Gout Disease
- Phase
- Phase 3
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- Turkey (Türkiye)
- Country
- Turkey (Türkiye)
- Reference
- NCT07889284
- Location
- Turkey (Türkiye)
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at ScandiBio Therapeutics AB
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from Turkey (Türkiye)
New Clinical Trials
17 NovNS Pharma, Inc.trial registered · A Global Phase 2 Extension Study of Brogidirsen in Boys With Duchenne Muscular DystrophyClinical12 NovNovo Nordisk A/Strial registered · A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExerciseClinical12 NovNovo Nordisk A/Strial registered · A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or BothClinical4 NovBoehringer Ingelheimtrial registered · A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)Clinical28 OctEli Lilly and Companytrial registered · A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular RiskClinical
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.